Alex Morgan
Angel Investor
Los Angeles, United States
Alex Morgan is a seed investor in Los Angeles focused on Biotechnology and Health Care. Alexandra Patricia Morgan Carrasco is an American soccer player, Olympic gold medalist, and FIFA Women's World Cup champion. She is a forward for Orlando Pride in the National Women's Soccer League and the United States national team.
- Total investments:
- 25
- Last investment:
- Lead investor:
- 36%
Last updated:
For AI agents: llms.txt
Industries Alex Morgan invests in
Stages Alex Morgan invests in
Countries Alex Morgan invests in
Investment Focus
Industry
- Biotechnology 6 (24%)
- Health Care 5 (20%)
- Medical Device 4 (16%)
- Sports 3 (12%)
- Medical 3 (12%)
Stage
- Seed 6 (24%)
- Series B 5 (20%)
- Series A 4 (16%)
- Series C 3 (12%)
- Funding Round 2 (8%)
Country
- United States 14 (56%)
- Canada 1 (4%)
- Portugal 1 (4%)
- Australia 1 (4%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Rad AI
|
Rad AI develops an artificial intelligence automated report generation platform to automate repetitive tasks for radiologists. Its platform integrates with existing workflow, automating repetitive tasks, and enabling radiologists to improve radiology workflow that maximizes efficiency and accuracy while reducing burnout for radiologists andimproving patient care. | $60M / Series C / Jan 25, 2025 | |
Synex Medical
|
Synex Medical develops non-invasive blood testing technology. This portable device will allow users to monitor metabolite concentrations without having to penetrate skin. They use a miniaturized magnetic resonance system to detect blood metabolites. The system only consists of magnets and radio waves, meaning there are no negative health effects. | $21.8M / Series A / Sep 22, 2024 | |
Neurode
|
Neurode is developing a non-invasive wearable device to improve cognitive performance for people with neurological conditions like ADHD. The headset aims to treat and monitor the symptoms of ADHD as well as a paired app that tracks your improvements and shares them with your clinician. | $3.5M / Pre-Seed / Sep 13, 2024 | |
Unrivaled
|
Unrivaled operates as a professional women's basketball league. | Seed / May 30, 2024 | |
|
Rad AI
|
Rad AI develops an artificial intelligence automated report generation platform to automate repetitive tasks for radiologists. Its platform integrates with existing workflow, automating repetitive tasks, and enabling radiologists to improve radiology workflow that maximizes efficiency and accuracy while reducing burnout for radiologists andimproving patient care. | $50M / Series B / May 07, 2024 | |
Nourish
|
Nourish is a healthcare technology company that connects patients with registered dietitians through virtual nutrition counseling services covered by insurance plans. The platform allows users to find dietitians based on their health goals and attend appointments through telehealth, while also offering tools for meal tracking, goal monitoring, andnutrition guidance through its mobile application. Nourish works with registered dietitian nutritionists who provide support for conditions such as diabetes, weight management, cardiovascular health, eating disorders, and pediatric nutrition care. The company states that it partners with major insurance providers to reduce out-of-pocket costs for patients and offers ongoing nutritional care through recurring consultations. In addition to patient services, Nourish publishes educational resources and uses data-driven approaches to support personalized nutrition planning and long-term health management. | $35M / Series A / Mar 27, 2024 | |
Encellin
|
Encellin develops a novel thin-film cell encapsulation device for cell-based therapeutics. It has dedicated experts focused on the investigation and advancement of next-generation therapies. It aims to help patients with chronic diseases, starting with Type 1 diabetes. It was founded in 2016 and is headquartered in San Francisco, California. | $9.9M / Series A / Dec 13, 2023 | |
Vivodyne
|
Vivodyne develops lifelike human organs for drug testing and research purposes. The company utilizes robotic systems and artificial intelligence to create realistic human tissues that simulate various organ functions. This innovative approach allows for efficient testing of pharmaceuticals, aiming to replace traditional animal testing methods. Byproducing over 100,000 human tissues in a short timeframe, Vivodyne enhances the predictive accuracy of drug responses in humans. The organization is committed to improving the preclinical drug testing process, providing valuable insights that can lead to more effective therapies. Through its advanced technology, Vivodyne contributes to the evolution of biomedical research and development. | $38M / Seed / Nov 22, 2023 | |
Synchron
|
Synchron manufactures and markets a medical device that can be delivered to the brain with a catheter to record neuron signals that might be used to control an advanced prosthetic. | $75M / Series C / Dec 15, 2022 | |
Soccer Post
|
Soccer Post operates as a chain of soccer specialty stores. | Private Equity / Nov 21, 2022 | |
| See all 25 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Alex Morgan invest in?
Alex Morgan invests primarily in Biotechnology, Health Care and Medical Device startups, most often at Seed and Series B stage. Most of the 25 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Alex Morgan last invest?
The most recent investment recorded for Alex Morgan closed in Jan 2025. Shizune tracks 25 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
